ZOGENIX, INC. (NASDAQ:ZGNX) Files An 8-K Termination of a Material Definitive AgreementItem 1.02
On August1, 2017, Zogenix, Inc., a Delaware corporation (the “Company”) and Durect Corporation, a Delaware corporation (“Durect”) entered into a Termination Agreement (the “Termination Agreement”), which terminates the Development and License Agreement dated July11, 2011, by and between the Company and Durect (as amended, the “Durect Agreement”). Under the Durect Agreement, Durect granted to the Company worldwide development and commercialization rights to Relday. Relday is an investigational long-acting formulation of risperidone, an atypical anti-psychotic agent.
Under the Termination Agreement, the Company’s development and commercialization rights are returned to Durect, and the Company will transfer to Durect all regulatory filings and development information related to Relday.
About ZOGENIX, INC. (NASDAQ:ZGNX)
Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company’s areas of focus are epilepsy and schizophrenia. Its lead product candidate, ZX008, is a low-dose fenfluramine. The Company is also engaged in the development of Relday, which is a long-acting injectable formulation of risperidone indicated for the treatment of symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. The Company is also engaged in manufacturing Sumavel DosePro (sumatriptan injection), a needle-free delivery system, which it sells to Endo Ventures Bermuda Limited and Endo Ventures Limited. Its DosePro technology is a drug delivery system designed for self-administration of a pre-filled, single dose of liquid drug, subcutaneously, without a needle.
